Is PT-141 (Bremelanotide) Legal in Maryland?

The Federal Legal Framework for PT-141

PT-141 (Bremelanotide) has a clear federal legal identity. The FDA approved it in June 2019 under the brand name Vyleesi, manufactured by AMAG Pharmaceuticals, specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval created a legal, commercially available product any licensed U.S. Prescriber may order. [1]

FDA Approval and Indication

The approval rested primarily on two Phase 3 trials, RECONNECT Study 1 and Study 2 (combined N=1,267), where Bremelanotide produced statistically significant improvements in the Female Sexual Function Index desire domain and a decrease in distress scores versus placebo at 24 weeks. [2] The FDA label specifies the 1.75 mg subcutaneous auto-injector dose, with a ceiling of one injection per 24-hour period and no more than one per sexual activity event. [1]

Because Vyleesi exists as an approved drug, any prescriber writing for it is on solid legal ground regardless of which U.S. State the patient resides in. Maryland is no exception.

DEA Scheduling

Bremelanotide is not listed in any DEA Schedule I through V under the Controlled Substances Act. [3] That means no state-level prescription monitoring program (PMP) reporting is required in Maryland, and pharmacies face no DEA quota restrictions on dispensing it. Patients do not need to use a specific PDMP-connected pharmacy. This distinguishes PT-141 sharply from testosterone, ketamine, and other commonly compounded hormone or peptide therapies.

The FDA Bulk Compounding List and What It Means

In June 2023, the FDA finalized its placement of Bremelanotide on the Category 2 list under Section 503B of the Federal Food, Drug, and Cosmetic Act. [4] Category 2 means the FDA has concluded that compounding the substance from bulk powder by large outsourcing facilities raises concerns about clinical necessity, because an FDA-approved finished product (Vyleesi) already exists.

The Category 2 designation does NOT automatically prohibit a 503A traditional compounding pharmacy from preparing a patient-specific Bremelanotide formulation when a licensed prescriber determines the approved product is clinically unsuitable for that patient. The FDA's own guidance on 503A compounding acknowledges that patient-specific compounding for documented clinical need operates under a separate legal standard. [5] the regulatory risk to the compounding pharmacy is meaningfully higher after a Category 2 listing, and many 503B outsourcing facilities have stopped bulk production of Bremelanotide entirely.

Maryland State Law: What Actually Governs PT-141 Here

Maryland does not have a standalone statute specifically addressing PT-141 or Bremelanotide by name. The relevant legal structure is built from three overlapping state frameworks: pharmacy practice law, medical practice standards, and telehealth regulations.

Maryland Pharmacy Practice Act and Compounding

The Maryland Board of Pharmacy regulates all drug compounding under COMAR 10.34.20 and enforces United States Pharmacopeia (USP) General Chapter 795 (non-sterile) and 797 (sterile) standards. [6] Subcutaneous injectable Bremelanotide is a sterile preparation, so any Maryland compounding pharmacy producing it must comply with USP 797 cleanroom, beyond-use dating, and sterility testing requirements.

Maryland-licensed pharmacies that compound Bremelanotide for a specific patient with a valid prescription from a licensed clinician are operating within state law, provided they meet USP 797 requirements and the federal 503A framework. Pharmacies shipping into Maryland from out of state must hold a Maryland non-resident pharmacy permit. [7]

The Prescriber-Patient Relationship Requirement

Maryland's Medical Practice Act (Health Occupations Article, Title 14) and COMAR 10.32.08 require a valid prescriber-patient relationship before any prescription drug can be ordered. For PT-141, this means a clinician must conduct a medical evaluation (history, review of systems, and assessment of HSDD or other documented indication) before issuing a prescription. [8]

Issuing a PT-141 prescription without any clinical evaluation, such as ordering from an unregulated online vendor that provides a "pro forma" questionnaire with no real physician review, violates Maryland law. The Maryland State Board of Physicians has pursued disciplinary action against prescribers who issue controlled-substance prescriptions without proper evaluations; the same standards apply to non-controlled prescription drugs when a formal complaint is filed. [9]

Telehealth Prescribing in Maryland

Maryland permits telehealth prescribing under COMAR 10.32.08.07, provided the clinician holds an active Maryland license, establishes a clinically appropriate relationship with the patient via synchronous audiovisual communication, documents the encounter in a medical record, and follows the same standard of care required for an in-person visit. [8]

Asynchronous or questionnaire-only telehealth encounters are legally insufficient under Maryland standards for initiating a new prescription for PT-141. The clinician must be able to assess the patient in real time. Once an initial synchronous visit is completed and a prescription is issued, follow-up refill communications may use asynchronous methods if the prescriber's clinical judgment supports it.

Who Qualifies for PT-141 in Maryland?

The FDA-approved indication is acquired, generalized HSDD in premenopausal women. Off-label prescribing for other populations, including postmenopausal women and men with psychogenic erectile dysfunction, is legal under Maryland and federal law, but the evidentiary base differs between these groups.

Evidence in Premenopausal Women (FDA-Approved Indication)

In the combined RECONNECT trials (N=1,267), Bremelanotide 1.75 mg produced a statistically significant increase of 0.5 points on the Female Sexual Function Index desire domain versus 0.3 points for placebo (P<0.001) and a decrease of 0.3 points on the Female Sexual Distress Scale-Desire/Arousal/Orgasm score versus 0.1 for placebo (P<0.001) at 24 weeks. [2] Nausea was the most common adverse event, occurring in approximately 40% of Bremelanotide-treated patients versus 1% placebo. [1]

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges Bremelanotide as a treatment option for HSDD in premenopausal women, stating: "We suggest offering pharmacological treatment (flibanserin or Bremelanotide) to premenopausal women with HSDD who prefer pharmacological therapy after discussion of benefits and risks." [10]

Off-Label Use in Men

Several early phase studies examined Bremelanotide in men with erectile dysfunction. A double-blind crossover trial by Diamond et al. (N=302) found that intranasal PT-141 10 mg produced erectile responses sufficient for intercourse in 67% of men with organic erectile dysfunction versus 25% placebo (P<0.001). [11] The subcutaneous formulation used today was not the route studied in that trial, and the FDA has not approved any PT-141 product for male sexual dysfunction. Prescribing for men is off-label in Maryland, which is legal but shifts the burden of documentation and informed consent to the prescribing clinician.

Off-Label Use in Postmenopausal Women

Postmenopausal women were excluded from the RECONNECT key trials. A smaller study by Simon et al. (N=99) found improvements in FSFI desire scores with Bremelanotide 1.75 mg versus placebo in postmenopausal women not using hormone therapy, though the sample size limits generalizability. [12] Maryland clinicians may prescribe for this population off-label with documented informed consent.

How to Get PT-141 (Bremelanotide) in Maryland

Getting a legal PT-141 prescription in Maryland requires three steps: a qualifying clinical evaluation, a valid prescription from a Maryland-licensed clinician, and dispensing through a licensed pharmacy.

Step 1. Clinical Evaluation

A Maryland-licensed physician, nurse practitioner, or physician assistant with prescribing authority must conduct a medical evaluation. For HSDD, this typically includes a validated symptom scale such as the FSFI or FSDS-R, a medication review (antidepressants and hormonal contraceptives can suppress desire), and a cardiovascular history given that Bremelanotide transiently elevates blood pressure by approximately 6 mmHg systolic and 3 mmHg diastolic for about 12 hours post-dose. [1]

Step 2. Prescription Options

The prescriber may write for FDA-approved Vyleesi (Bremelanotide 1.75 mg/0.3 mL auto-injector). Most major retail pharmacies in Maryland can fill this. Alternatively, if the prescriber documents a clinical reason the approved product is unsuitable (for example, a patient who cannot tolerate a fixed 1.75 mg dose and needs titration starting at 1 mg), a 503A-compliant compounding pharmacy may prepare a patient-specific formulation. [5]

Given the 2023 Category 2 FDA listing, the prescriber's documentation of clinical necessity is particularly important for any compounded version. A compounding pharmacy that receives a PT-141 prescription without that documentation may decline the order to limit regulatory exposure.

Step 3. Pharmacy Dispensing

Maryland-licensed retail pharmacies can dispense Vyleesi with a valid prescription. Compounded Bremelanotide must come from a USP 797-compliant sterile compounding pharmacy. Patients ordering from out-of-state compounding pharmacies should verify the pharmacy holds a Maryland non-resident pharmacy permit through the Maryland Board of Pharmacy's online license lookup. [7]

Telehealth platforms operating in Maryland, including HealthRX, connect patients to Maryland-licensed clinicians who can complete the synchronous evaluation and route a prescription to a verified pharmacy partner.

Safety Considerations Maryland Prescribers Must Address

A legal prescription does not eliminate clinical risk. Maryland clinicians prescribing PT-141 must document a cardiovascular risk assessment before initiating therapy.

Blood Pressure and Cardiovascular Risk

The FDA label contains a warning about transient blood pressure increases. In the RECONNECT pooled safety dataset, mean maximum systolic blood pressure increased by 6.1 mmHg and diastolic by 3.1 mmHg within approximately 4 hours of dosing, returning to baseline within 12 hours. [1] The label states the drug should not be used in patients with known cardiovascular disease, and patients should not use it with other blood-pressure-raising agents. [1]

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts occurred in 1% of patients in trials. Patients with darker skin phototypes or a history of melasma may be at higher risk. [2] This is a class effect of melanocortin agonists and reflects MC1R activity.

Drug Interactions

Bremelanotide slows gastric emptying and may reduce the rate of absorption of co-administered oral medications. The FDA label specifically warns about concomitant use with naltrexone and indomethacin because their systemic exposure may be reduced. [1] Maryland pharmacists conducting medication therapy management reviews should check this interaction in every patient profile before dispensing. [13]

Nausea Management

Nausea affects roughly 40% of patients and is the primary reason for discontinuation. Pre-treatment with ondansetron 4 mg orally approximately 30 minutes before the Bremelanotide injection reduces nausea severity in clinical practice, though no published randomized trial has specifically examined this combination at the time of writing. Clinicians should discuss this approach with patients and document the rationale.

Regulatory Gray Areas to Know About

Not every PT-141 product advertised online is legal to purchase in Maryland. Several specific scenarios carry legal risk.

Research Chemical Vendors

Some websites sell Bremelanotide acetate powder or solution labeled "for research use only" and "not for human use." Purchasing these products for personal injection is illegal under the Federal Analog Act provisions and state consumer protection law, and constitutes use of an unapproved drug outside any prescriber relationship. Maryland's Health Occupations Article does not create a safe harbor for self-administration of compounded injectables obtained without a prescription. [8]

International Online Pharmacies

Importing Bremelanotide from non-FDA-registered foreign pharmacies violates the Federal Food, Drug, and Cosmetic Act. The FDA's personal importation policy does not cover injectable biologics or peptides where an FDA-approved domestic alternative exists. [14] Vyleesi is available domestically, so the personal importation exemption is unlikely to apply.

Veterinary-Grade Products

No veterinary-approved Bremelanotide product exists. Any product marketed as a veterinary peptide is either mislabeled or counterfeit and carries unknown sterility and potency risks.

Comparing Vyleesi to Compounded PT-141 in Maryland

The practical choice most Maryland patients face is between FDA-approved Vyleesi and compounded Bremelanotide from a 503A pharmacy.

| Factor | Vyleesi (FDA-Approved) | Compounded PT-141 (503A) | |---|---|---| | Legal certainty | High | Moderate (requires clinical necessity documentation) | | Dose flexibility | Fixed 1.75 mg only | Variable (e.g., 0.5 mg, 1 mg titration possible) | | Insurance coverage | Rare; GoodRx price approx. $900/dose | Cash pay; typically $30-80/dose depending on pharmacy | | Sterility assurance | FDA-registered manufacturer | USP 797 compliance by pharmacy; pharmacy-specific | | Availability in MD | Major retail pharmacies | USP 797-compliant compounding pharmacies only |

Cost is the primary driver of compounded use in Maryland. At approximately $900 per auto-injector for Vyleesi, most patients without specialty drug coverage choose compounded preparations for long-term use, provided the prescriber has documented the clinical necessity. [15]

What Maryland Clinicians Must Document

Maryland prescribers face no unique state-specific PT-141 documentation law beyond standard medical practice standards, but best practices include:

A complete sexual history using a validated tool such as the FSFI, FSDS-R, or IIEF (for male patients). A medication reconciliation specifically screening for antidepressants, hormonal contraceptives, and antihypertensives. A cardiovascular risk assessment covering blood pressure, history of cardiac disease, and concurrent medications. Signed informed consent covering the common adverse effects (nausea, flushing, transient hypertension, hyperpigmentation). For compounded preparations, a written statement of clinical necessity explaining why the FDA-approved product is not appropriate for this specific patient.

The American Society for Reproductive Medicine (ASRM) guidance on sexual dysfunction recommends a biopsychosocial assessment before initiating pharmacotherapy for HSDD, a standard fully consistent with Maryland's COMAR requirements. [16]